Abstract
Background Hypertensive Disorders of Pregnancy (HDP) complicate 5-10% of pregnancies globally: 2-5% preeclampsia, 3% gestational hypertension, and 0.5-2% chronic hypertension. It is epidemiologically well established that adverse health effects of HDP do not end with the pregnancy: these conditions are associated with increased lifetime cardiovascular disease (CVD) risks. However, intervention trial data in the early years postpartum after HDP, focussed on early intervention to reduce women’s ongoing CVD risks after HDP, is sparse.
Methods The Blood Pressure Postpartum Trial (BP2) is a 3-arm randomised controlled trial investigating three different methods of follow-up and lifestyle behaviour change in the first 12 months postpartum following a pregnancy affected by HDP. The trial was prospectively registered on the Australian and New Zealand Clinical trials registry (registration: ACTRN12618002004246) and the study protocol has previously been published (Henry A et al, Pregnancy Hypertension 2020; 22: 1-6). This manuscript details the pre-analysis, pre-specified Statistical Analysis Plan.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ACTRN12618002004246
Clinical Protocols
https://doi.org/10.1016/j.preghy.2020.07.001
Funding Statement
This study was funded by the NSW Health Translational Research Grants Scheme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee of the South Eastern Sydney Local Health District gave ethical approval for this work (ref 18/193).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviations and Definitions
- BP2
- Blood Pressure Postpartum Study
- CH
- Chronic hypertension
- CH+PE
- Chronic hypertension with superimposed preeclampsia
- CRP
- C-reactive protein
- CVD
- Cardiovascular disease
- eGFR
- Estimated glomerular filtration rate
- GH
- Gestational hypertension
- GHS
- Get Healthy Service
- GP
- General Practitioner
- HDP
- Hypertensive disorders of pregnancy
- HOMA
- Homeostatic assessment (of insulin resistance)
- hsCRP
- High-sensitivity C-reactive protein
- PE
- Preeclampsia
- PP
- Postpartum
- SAP
- Statistical Analysis Plan
- SD
- Standard Deviation
- UNSW
- University of New South Wales
